NeuroSense Announces First Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

Related Keywords

Boston ,Massachusetts ,United States ,Australia ,Cambridge ,Cambridgeshire ,United Kingdom ,Canada , ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Neurosense Therapeutics Ltd ,Neurosense Therapeutics ,Biomarker Studies ,Massachusetts General Hospital ,Investigational New Drug ,Fast Track ,Orphan Drug Designation ,Initiate Phase ,Primec Study ,Interim Unaudited Statements ,Sense Therapeutics ,Neurosense ,